Search

Your search keyword '"Turchetto, L."' showing total 133 results
Start Over Author "Turchetto, L."
133 results on '"Turchetto, L."'

4. TK007 phase II study final analysis. Genetically modified donor lymphocytes abate transplant related mortality and increase leukaemia-free survival providing early immune reconstitution after haploidentical haematopoietic stem cell transplantation

Author

Lupo Stanghellini, M. T., Ciceri, F., Bonini, C., Bondanza, A., Traversari, C., Toma, S., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S. K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Fleischhauer, K., Ponzoni, M., Vago, L., Santoro, A., Todisco, E., Apperley, J., Slavin, S., Weissinger, E., Hertenstein, B., Bregni, M., Gallo Stampino, C., Bruzzi, P., and Bordignon, C.

Published
2008

5. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Author

Bartunek, Jozef, Terzic, Andre, Davison, Beth A, Filippatos, Gerasimos S, Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G, Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M, Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L, Shochat, Michael K, Kasprzak, Jaroslaw D, Sanz Ruiz, Ricardo, Heyndrickx, Guy R, Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez Aviles, Francisco, Jimenez Quevedo, Pilar, Bayes Genis, Antoni, Hernandez Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A, Teerlink, John R, Gersh, Bernard J, Povsic, Thomas J, Henry, Timothy D, Metra, Marco, Hajjar, Roger J, Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, Wijns, W. i. l. l. i. a. m. Collaborators Clinical investigators, Dens, sites Belgium: Ziekenhuis Oost Limburg: J., Dupont, M., Mullens, W., Janssens, M., Dolatabadi, Hoˆpital Civil de Charleroi: D., De Bruyne, Y., Lalmand, J., Dubois, P., El Nakadi, B., Aminian, A., De Vuyst, E., Gurnet, P., Gujic, M., Blankoff, I., Guedes, CHU Mont Godinne UCL: A., Gabriel, L., Seldrum, S., Doyen, C., Andre´, M., Heyse, AZ Glorieux: A., Van Durme, F., Verschuere, J., Legrand, Domaine Universitaire du Sart Tilman: V., Gach, O., D’Orio, V., Davin, L., Lancellotti, P., Baudoux, E., Ancion, A., Dulgheru, R., Vanderheyden, OLV Ziekenhuis Aalst – Cardiologie: M., Bartunek, J., Wijns, W., Verstreken, S., Penicka, . M., Gelev, P. Meeus Bulgaria: Tokuda Hospital Sofia: V., Zheleva Kichukova, I., Parapunova, R., Melamed, R., Sardovski, S., Radev, O., Yordanov, A., Radinov, A., Nenov, D., Amine, I., Petrov, City Hospital Clinic Cardiology Center: I., Kichukov, K., Nikitasov, L., Stankov, Z., Stoyanov, H., Tasheva Dimitrova, I., Angelova, M., Dimitrov, E., Minchev, M., Garvanski, I., Botev, C., Polomski, P., Alexandrovska University Hospital, Vassilev, Sofia: D., Karamfiloff, K., Tarnovska Kadreva, R., Vladimirova, L., Dimitrov, G., Hadzhiev, E., Tzvetkova, G., Andreka, . M. Atanasova Hungary: Gottsegen Gyo¨ rgy Orszagos Kardiologiai Inte´zet: P., Fontos, G., Fabian, J., Csepregi, A., Uzonyi, G., Gelei, A., Edes, Debreceni Egyetem Orvos e´s Ege´szse´gtudomanyi Centrum Altalanos Orvostudomanyi Kar Kardiologia Inte´zet: I., Balogh, L., Vajda, G., Darago, A., Gergely, S., Fulop, T., Jenei, C., Horvath, Pe´csi Tudomanyegyetem Klinikai Ko¨zpont Szıvgyogyaszati Klinika: I., Magyari, B., Nagy, A., Cziraki, A., Faludi, R., Kittka, B., Alizadeh, H., Merkely, Semmelweis Egyetem Varosmajori Szıv e´s Ergyogyaszati Klinika: B., Geller, L., Farkas, P., Szombath, G., Foldes, G., Skopal, J., Kovacs, A., Kosztin, A., Gara, E., Sydo, N., Nyolczas, MH Ege´szse´gu¨gyi Ko¨zpont Kardiologiai Osztaly: N., Kerecsen, G., Korda, A., Kiss, . M., Borsanyi, T., Polgar, B., Muk, B., Sharif, Z. Bari Ireland: HRB Clinical Research Facility: F., Atar, Y. M. Smyth Israel:Western Galilee Hospital: S., Shturman, A., Akria, L., Kilimnik, M., Brezins, M., Halabi, Ziv Medical Center: M., Dally, N., Goldberg, A., Aehab, K., Rosenfeld, I., Levinas, T., Saleem, D., Katz, Barzilai Medical Center: A., Plaev, T., Drogenikov, T., Nemetz, A., Barshay, Y., Jafari, J., Orlov, I., Nazareth Hospital EMMS: M. Omory, N. Kogan Nielsen, Shochat, Hillel Yaffe Medical Center: M., Shotan, A., Frimerman, A., Meisel, S., Asif, A., Sofer, O., Blondheim, D. S., Vazan, A., Metra, L. Arobov Italy: A. O. Spedali Civili di Brescia: M., Bonadei, I., Inama, L., Chiari, E., Lombardi, C., Magatelli, M., Russo, D., Lazzarini, V., Carubelli, V., Vassanelli, AOUI Verona – Borgo Trento Hospital: C., Ribichini, Flavio Luciano, Bergamini, C., Krampera, Mauro, Cicoria, M. A., Zanolla, L., Dalla Mura, D., Gambaro, A., Rossi, A., Pesarini Poland: Jagiellonian University Department of Cardiac, G., Musialek, Vascular Diseases at John Paul II Hospital in Krakow: P., Mazurek, A., Drabik, L., Ka˛dzielski, A., Walter, Z., Dzieciuch Rojek, M., Rubis, P., Plazak, . W., Tekieli, L., Podolec, J., Orczyk, W., Sutor, U., Zmudka, K., Olszowska, M., Podolec, P., Gruchala, Uniwersyteckie Centrum Kliniczne: M., Ciecwierz, D., Mielczarek, M., Burakowski, S., Chmielecki, M., Zielinska, M., Frankiewicz, A., Wdowczyk, J., Stopczynska, I., Bellwon, J., Mosakowska, K., Nadolna, R., Wroblewska, J., Rozmyslowska, M., Rynkiewicz, M., Marciniak, I., Raczak, G., Tarnawska, M., Taszner, M., Kasprzak, Bieganski Hospital: J., Plewka, M., Fiutowska, D., Rechcinski, T., Lipiec, P., Sobczak, M., Weijner Mik, P., Wraga, M., Krecki, R., Markiewicz, M., Haval Qawoq, D., Wojakowski, Gornosla˛skie Centrum Medyczne Sla˛skie j. Akademii Medycznej: W., Ciosek, J., Dworowy, S., Gaszewska Zurek, E., Ochala, A., Cybulski, W., Jadczyk, T., Wanha, W., Parma, Z., Kozlowski, M., Dzierzak, M., Markiewicz Serbia: Clinical Hospital Center Zvezdara, M., Arandjelovic, Cardiology Clinic: A., Sekularac, N., Boljevic, D., Bogdanovic, A., Zivkovic, S., Cvetinovic, N., Loncar, G., Clinical Centre of Serbia, Beleslin, Cardiology Clinic: B., Nedeljkovic, M., Trifunovic, D., Giga, V., Banovic, M., Nedeljkovic, I., Stepanovic, J., Vukcevic, V., Djordjevic Dikic, A., Dobric, M., Obrenovic Kircanski, B., Seferovic, Cardiology Clinic: P., Orlic, D., Tesic, M., Petrovic, O., Milinkovic, I., Simeunovic, D., Jagic, Clinical Center of Kragujevac: N., Tasic, M., Nikolic, D., Miloradovic, V., Djurdjevic, P., Sreckovic, M., Zornic, N., Clinical Hospital Center Bezanijska Kosa, Radovanovic, Cardiology Department: S., Saric, J., Hinic, S., Djokovic, A., Ðordevic, S., Bisenic, V., Markovic, O., Stamenkovic, S., Malenkovic, V., Tresnjak, J., Misic, G., Cotra, D., Tomovic, L., Vuckovic, V., Clinic of Emergency Internal Medicine, Obradovic, Military Medical Academy: S., Jovic, Z., Vukotic, S., Markovic, D., Djenic, N., Ristic Andjelkov, A., Bayes Genis, D. Ljubinka Spain: Hospital Universitario Germans Trias I. Pujol: A., Rodriguez Leor, O., Labata, C., Vallejo, N., Ferrer, E., Batlle, M., Fernandez Aviles, Hospital General Universitario Gregorio Mara~non: F., Sanz Ruiz, R., Casado, A., Loughlin, G., Zatarain, E., Anguita, J., Ferna ndez Santos, M. E., Pascual, C., Bermejo, J., Hernandez Garcia, Hospital Clinico Universitario Virgen de la Victoria: J. M., Jimenez Navarro, M., Dominguez, A., Carrasco, F., Mu~noz, A., Garcia Pinilla, J. M., Ruiz, J., Queipo de Llano, M. P., Hernandez, A., Fernandez, A., Jimenez Quevedo, Hospital Clinico San Carlos: P., Guerra, R., Biagioni, C., Gonzalez, R. A., Gomez deDiego, J. J., Mansson Broberg, L. Perez de Isla Sweden: Karolinska University Hospital: A., Sylve´n, C., Leblanc, K., Winter, R., Blomberg, P., Gunyeli, E., Ruck, A., Silva, C., Fo¨rstedt Switzerland: CardioCentro Ticino, J., Moccetti, Switzerland: T., Rossi, M., Pasotti, E., Petrova, I., Crljenica, C., Monti, C., Murzilli, R., Su¨rder, D., Moccetti, M., Turchetto, L., Locicero, V., Chiumiento, L., Maspoli, S., Mombelli, M., Anesini, A., Biggiogero, M., Ponti, G., Camporini, C., Polledri, S., Hill, G. Dolci United Kingdom: Kings College Hospital: J., Plymen, C., Amin Youssef, G., Mcdonagh, T., Drasar, E., Mijovic, A., Jouhra, F., Mcloman, D., Dworakowski, R., Webb, I., Byrne, J., and Potter, V.

Subjects
0301 basic medicine, Male, Cardiopoiesis, Cardiovascular disease, Disease severity, Marker, Precision medicine, Regenerative medicine, Stem cell, Target population, Adult, Aged, Double-Blind Method, Female, Heart Failure, Humans, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia, Prospective Studies, Treatment Outcome, Young Adult, Cardiology and Cardiovascular Medicine, Cell- and Tissue-Based Therapy, mesenchymal stem-cells, 030204 cardiovascular system & hematology, Cardiorespiratory Medicine and Haematology, outcomes, Fast-Track Clinical Research, Sudden cardiac death, 0302 clinical medicine, Ischemia, cardiovascular disease, Clinical endpoint, target population, CHART Program, Ejection fraction, bone-marrow, Heart Failure/Cardiomyopathy, 3. Good health, Cohort, Cardiology, Fast Track, disease severity, delivery, medicine.medical_specialty, precision medicine, Clinical Sciences, regenerative medicine, 03 medical and health sciences, cardiopoiesis, Internal medicine, medicine, Adverse effect, marker, disease, business.industry, medicine.disease, mortality, Confidence interval, Clinical trial, stem cell, Editor's Choice, 030104 developmental biology, predictors, Cardiovascular System & Hematology, Heart failure, business
Abstract

Altres ajuts: This work was supported by Celyad, SA (Mont-Saint-Guibert, Belgium). Celyad has received research grants from the Walloon Region (Belgium, DG06 funding). Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann–Whitney estimator 0.54, 95% confidence interval [CI] 0.47–0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200–370 mL (60% of patients) (Mann–Whitney estimator 0.61, 95% CI 0.52–0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Published
2017

7. TK007 phase II study final analysis. Genetically modified donor lymphocytes abate transplant related mortality and increase leukaemia-free survival providing early immune reconstitution after haploidentical haematopoietic stem cell transplantation

Author

Stanghellini MTL, CICERI, FABIO, BONINI , MARIA CHIARA, BONDANZA , ATTILIO, Traversari C, Toma S, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Fleischhauer K, PONZONI , MAURILIO, Vago L, Santoro A, Todisco E, Apperley J, Slavin S, Weissinger E, Hertenstein B, Bregni M, Stampino CG, Bruzzi P, BORDIGNON, CLAUDIO, Stanghellini, Mtl, Ciceri, Fabio, Bonini, MARIA CHIARA, Bondanza, Attilio, Traversari, C, Toma, S, Salomoni, M, Turchetto, L, Colombi, S, Bernardi, M, Peccatori, J, Pescarollo, A, Servida, P, Magnani, Z, Perna, Sk, Valtolina, V, Crippa, F, Callegaro, L, Spoldi, E, Fleischhauer, K, Ponzoni, Maurilio, Vago, L, Santoro, A, Todisco, E, Apperley, J, Slavin, S, Weissinger, E, Hertenstein, B, Bregni, M, Stampino, Cg, Bruzzi, P, and Bordignon, Claudio

Published
2008

8. HAPLO-SCT WITH TK plus LYMPHOCYTES PRODUCE LEUKEMIA FREE SURVIVAL COMPARABLE TO UNRELATED BONE MARROW AND CORD BLOOD TRANSPLANTATION IN HIGH RISK ACUTE LEUKEMIA: 'TK007' PHASE II STUDY FINAL ANALYSIS

Author

Stanghettini, M. T. Lupo, Ciceri, F., Bonini, C., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S. K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L., Armando Santoro, Todisco, E., Apperley, J., Slavin, S., Weissinger, E. M., Hertenstein, B., Bregni, M., Stampino, C. Gallo, Bruzzi, P., Stanghettini, Mtl, Ciceri, Fabio, Bonini, MARIA CHIARA, Bondanza, Attilio, Traversari, C, Salomoni, M, Turchetto, L, Colombi, S, Bernardi, M, Peccatori, J, Pescarollo, A, Servida, P, Magnani, Z, Perna, Sk, Valtolina, V, Crippa, F, Callegaro, L, Spoldi, E, Crocchiolo, R, Fleischhauer, K, Ponzoni, Maurilio, Vago, L, Santoro, A, Todisco, E, Apperley, J, Slavin, S, Weissinger, Em, Hertenstein, B, Bregni, M, Stampino, Cg, and Bruzzi, P.

Published
2008

9. SUICIDE GENE TRANSFER INTO DONOR LYMPHOCYTES ALLOWS EARLY AND EFFECTIVE IMMUNE-RECONSTITUTION AFTER FAMILY HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LEUKEMIAS: RESULTS OF THE TK007 STUDY

Author

BONINI, MARIA CHIARA, CICERI, FABIO, BONDANZA, ATTILIO, PONZONI, MAURILIO, BORDIGNON, CLAUDIO, Lupo, Smt, Traversari, C, Salomoni, M, Turchetto, L, Colombi, S, Bernardi, M, Peccatori, J, Magnani, Z, Perna, Sk, Valtolina, V, Crippa, F, Callegaro, L, Spoldi, E, Crocchiolo, R, Fleischhauer, K, Vago, L, Santoro, A, Todisco, E, Apperley, J, Slavin, S, Weissinger, Em, Hertenstein, B, Bregni, M, Gallo, Sc, Bruzzi, P, Bonini, MARIA CHIARA, Ciceri, Fabio, Lupo, Smt, Bondanza, Attilio, Traversari, C, Salomoni, M, Turchetto, L, Colombi, S, Bernardi, M, Peccatori, J, Magnani, Z, Perna, Sk, Valtolina, V, Crippa, F, Callegaro, L, Spoldi, E, Crocchiolo, R, Fleischhauer, K, Ponzoni, Maurilio, Vago, L, Santoro, A, Todisco, E, Apperley, J, Slavin, S, Weissinger, Em, Hertenstein, B, Bregni, M, Gallo, Sc, Bruzzi, P, and Bordignon, Claudio

Published
2008

10. Infusions of HSV-TK engineered donor lymphocytes promote the expansion of host-restricted viral-specific T lymphocytes and protect patients undergoing haploidentical stem cell transplantation from infectious mortality

Author

Provasi E, Stanghellini MTL, Magnani Z, Perna SK, Forcina A, Bernardi M, Peccatori J, Crippa F, Valtolina V, Salomoni M, Turchetto L, Toma S, Traversari C, Colombi S, Stampino CG, MANFREDI, ANGELO ANDREA M. A., BORDIGNON, CLAUDIO, CICERI , FABIO, BONDANZA , ATTILIO, ROVERE QUERINI , PATRIZIA, BONINI , MARIA CHIARA, Provasi, E, Ciceri, Fabio, Stanghellini, Mtl, Bondanza, Attilio, Magnani, Z, Perna, Sk, Forcina, A, Bernardi, M, Peccatori, J, Crippa, F, Valtolina, V, Salomoni, M, Turchetto, L, Toma, S, Traversari, C, Colombi, S, Stampino, Cg, ROVERE QUERINI, Patrizia, Manfredi, ANGELO ANDREA M. A., Bordignon, Claudio, and Bonini, MARIA CHIARA

Published
2007

12. Rapid and effective immune reconstitution with HSV-TK engineered donor lymphocyte add-backs after Haplo-HSCT

Author

BONINI , MARIA CHIARA, CICERI , FABIO, Lupo Stanghellini MT, BONDANZA , ATTILIO, Magnani Z, Perna SK, Bernardi M, Peccatori J, Pescarollo A, Servida P, Crippa F, Callegaro L, Vago L, Fleischhauer K, Salomoni M, Turchetto L, Toma S, Traversari C, Bruzzi P, Castagna L, Santoro A, Apperley J, Slavin S, Colombi S, Gallo Stampino C, Bregni M, BORDIGNON, CLAUDIO, Bonini, MARIA CHIARA, Ciceri, Fabio, Lupo Stanghellini, Mt, Bondanza, Attilio, Magnani, Z, Perna, Sk, Bernardi, M, Peccatori, J, Pescarollo, A, Servida, P, Crippa, F, Callegaro, L, Vago, L, Fleischhauer, K, Salomoni, M, Turchetto, L, Toma, S, Traversari, C, Bruzzi, P, Castagna, L, Santoro, A, Apperley, J, Slavin, S, Colombi, S, Gallo Stampino, C, Bregni, M, and Bordignon, Claudio

Published
2006

13. Hsv-Tk engineered donor lymphocytes provide early immune reconstitution and control of Gvhd after haplo-identical hemopoietic stem cell transplantation

Author

BONINI , MARIA CHIARA, CICERI , FABIO, Apperley J, Slavin S, Marktel S, BONDANZA , ATTILIO, Magnani Z, Perna SK, Zappone E, Pescarollo A, Callegaro L, Bernardi M, Gallo Stampino C, Salomoni M, Turchetto L, Servida P, Bregni M, BORDIGNON, CLAUDIO, Bonini, MARIA CHIARA, Ciceri, Fabio, Apperley, J, Slavin, S, Marktel, S, Bondanza, Attilio, Magnani, Z, Perna, Sk, Zappone, E, Pescarollo, A, Callegaro, L, Bernardi, M, Gallo Stampino, C, Salomoni, M, Turchetto, L, Servida, P, Bregni, M, and Bordignon, Claudio

Published
2003

16. Infusion of suicide gene-modified donor T cells promotes a rapid and effective immune reconstitution and provides long-term survival after haploidentical hemaopoietic cell transplantation for the cure of patients with high-risk leukemia

Author

Bonini, C., primary, Ciceri, F., additional, Lupo Stanghellini, M.T., additional, Bondanza, A., additional, Magnani, Z., additional, Perna, S., additional, Bernardi, M., additional, Peccatori, J., additional, Servida, P., additional, Crippa, F., additional, Kaneko, S., additional, Valtolina, V., additional, Ferrari, M., additional, Provasi, E., additional, Salomoni, M., additional, Turchetto, L., additional, Toma, S., additional, Traversari, C., additional, Bruzzi, P., additional, Castagna, L., additional, Santoro, A., additional, Apperley, J., additional, Slavin, S., additional, Colombi, S., additional, Gallo Stampino, C., additional, Bregni, M., additional, and Bordignon, C., additional

Published
2008
Full Text
View/download PDF

17. Studies on the mechanisms of HTLV-I leukemogenesis

Author

Daniela Saggioro, Majone, F., Forino, M., Turchetto, L., and Chieco-Bianchi, L.

Subjects
Cell Transformation, Neoplastic, Leukemia, T-Cell, Micronucleus Tests, Transcription, Genetic, Genes, pX, Tumor Cells, Cultured, Humans, Tetradecanoylphorbol Acetate, Transfection, HTLV-I Infections, Methylation, DNA Damage, Plasmids
Abstract

The factors that regulate low viral expression and long latency after HTLV-I infection are poorly understood. To study the possible mechanisms involved in the regulation of gene expression and cell transformation, we studied whether (1) methylation could play a role in viral transcription, and (2) tax product could favor chromosomal instability. The results indicate that methylation of HTLV-I LTRs blocks their transcriptional activity and that tax protein triggers DNA damage.

Published
1992

18. Infusions of HSV-TK Engineered Donor Lymphocytes Effectively Protect Patients Undergoing Haploidentical Stem Cells Trasplantation (HSCT) from Infectious Mortality.

Author

Stanghellini, M.T. Lupo, primary, Bonini, C., additional, Provasi, E., additional, Bernardi, M., additional, Peccatori, J., additional, Bondanza, A., additional, Magnani, Z., additional, Perna, S.K., additional, Crippa, F., additional, Valtolina, V., additional, Salomoni, M., additional, Turchetto, L., additional, Toma, S., additional, Traversari, C., additional, Colombi, S., additional, Stampino, C. Gallo, additional, Bruzzi, P., additional, Castagna, L., additional, Apperley, J., additional, Slavin, S., additional, Ciceri, F., additional, and Bordignon, Claudio, additional

Published
2007
Full Text
View/download PDF

20. HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial.

Author

Ciceri, F., primary, Bonini, C., additional, Stanghellini, M.T. Lupo, additional, Bondanza, A., additional, Magnani, Z., additional, Perna, S., additional, Bernardi, M., additional, Peccatori, J., additional, Pescarollo, A., additional, Servida, P., additional, Crippa, F., additional, Callegaro, L., additional, Salomoni, M., additional, Turchetto, L., additional, Toma, S., additional, Bruzzi, P., additional, Castagna, L., additional, Santoro, A., additional, Apperley, J., additional, Slavin, S., additional, Colombi, S., additional, Stampino, C. Gallo, additional, Bregni, M., additional, and Bordignon, C., additional

Published
2005
Full Text
View/download PDF

24. Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.

Author

Vicenzi, E, primary, Bagnarelli, P, additional, Santagostino, E, additional, Ghezzi, S, additional, Alfano, M, additional, Sinnone, MS, additional, Fabio, G, additional, Turchetto, L, additional, Moretti, G, additional, Lazzarin, A, additional, Mantovani, A, additional, Mannucci, PM, additional, Clementi, M, additional, Gringeri, A, additional, and Poli, G, additional

Published
1997
Full Text
View/download PDF

27. Indicazioni e tecnica del trattamento in chirurgia aperta dell' impingement femoro-acetabolare.

Author

Ganz, R., Turchetto, L., and Leunig, M.

Abstract

Successful treatment of femoroacetabular impingement requires thorough knowledge of the impingement spectrum and precision in diagnosis. Substantial information may escape when not routinely using high-quality arthro-MRI including radial sequences. Early recognition of FAI is essential. It has to be followed by behavioral modification and even surgical treatment to eventually reduce or postpone osteoarthritis due to impingement. Physical therapy or pharmaceutical medication cannot influence the pathomechanical process or the adverse influence on the hip joint. Surgical treatment should be technically feasible and the benefit for the patient foreseeable. Open and arthroscopic techniques are not competitive; they should be applied according to the pathology rather than the surgeon's preference.We describe here the indication and techniques of open surgery for impingement hips with rather complex pathology, the workhorse for most procedures being surgical dislocation and the extended retinacular soft tissue flap. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

29. Protrusio acetabuli: new insights and experience with joint preservation.

Author

Leunig M, Nho SJ, Turchetto L, Ganz R, Leunig, Michael, Nho, Shane J, Turchetto, Luigino, and Ganz, Reinhold

Abstract

Protrusio acetabuli is identified on anteroposterior (AP) radiographs of the pelvis with an acetabular line projecting medial to the ilioischial line. We documented this radiographic sign and additional radiographic parameters in 19 patients (29 hips) with protrusio and compared the parameters to those of 29 older patients (29 hips) with advanced primary osteoarthritis (OA) but no protrusio and 12 younger patients (22 hips) with protrusio but no advanced OA. A negative acetabular roof angle and particularly large acetabular fossa were more apparent in younger patients; these hips suggest the destruction of a protrusio hip begins less in the medial joint area and more in the posteroinferior joint, and the mechanism is driven less by excessive medially directed forces but by a pincer impingement. While the indication for joint-preserving surgery currently consists primarily of a valgus femoral osteotomy based on AP radiographs and patient age, modern decision making also relies on cartilage evaluation and requires advanced surgical techniques. We conclude joint-preservation surgery must be tailored to the individual hip morphology. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

33. Genotyping in routine laboratory for detection of Factor V Leiden (1691G>A) and Prothrombin (20210G>A) mutations with the Invader®Assay Technology.

Author

Hanguehard, A., Morelle, M., Turchetto, L., Depasse, F., Samama, M.M., and Ronsin, C.

Abstract

Copyright of IBS, Immuno-analyse & Biologie Specialisee is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2004
Full Text
View/download PDF

37. Studio analitico su alcune tinture per capelli

Author

Turchetto, L., Cuozzo, V., Terracciano, M., Papetti, Patrizia, Percaccio, G., and Quercia, V.

Subjects
CHEMICAL ANALYSIS, HAIR DYE, CHEMICAL COMPOSITION, HAIR DYE, HAIR PRODUCT, CHEMICAL ANALYSIS, CHEMICAL COMPOSITION, LIQUID CHROMATOGRAPHY HIGH PRESSURE, HAIR PRODUCT, LIQUID CHROMATOGRAPHY HIGH PRESSURE
Published
1978

45. Hemophilia and nonprogressing human immunodeficiency virus type 1 infection

Author

Vicenzi, E., Bagnarelli, P., Santagostino, E., Ghezzi, S., Alfano, M., Sinnone, M.S., Fabio, G., Turchetto, L., Moretti, G., Lazzarin, A., Mantovani, A., Mannucci, P.M., Clementi, M., Gringeri, A., and Poli, G.

Subjects
HIV infection -- Development and progression, Viremia -- Measurement, Hemophiliacs -- Health aspects
Abstract

According to the authors' abstract of an article published in Blood, "Seven of 112 hemophiliacs infected with human immunodeficiency virus type-1 (HIV-1) before 1986 through contaminated plasma products are currently [...]

Published
1997

47. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Author

Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, and Fleischhauer K

Abstract

Background: Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality. We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality.Methods: In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation. The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per muL or more for two consecutive observations. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00423124.Findings: From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17-66) received haploidentical stem-cell transplants for high-risk leukaemia. Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34-127) from transplantation and 23 days (13-42) from infusion. Ten patients developed acute GVHD (grade I-IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene. Overall survival at 3 years was 49% (95% CI 25-73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation. After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days. No acute or chronic adverse events were related to the gene-transfer procedure.Interpretation: Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation.Funding: MolMed SpA, Italian Association for Cancer Research. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

49. Defective nef Alleles in a Cohort of Hemophiliacs with Progressing and Nonprogressing HIV-1 Infection

Author

Patrizia Bagnarelli, Fabrizio Veglia, Alessandra Gatti, Massimo Clementi, Elisa Vicenzi, Lucia Turchetto, Alessandro Gringeri, Chiara Bovolenta, Elena Santagostino, Guido Poli, Andrea Brambilla, Brambilla, A, Turchetto, L, Gatti, A, Bovolenta, C, Veglia, F, Santagostino, E, Gringeri, A, Clementi, Massimo, Poli, Guido, Bagnarelli, P, and Vicenzi, E.

Subjects
Adult, Adolescent, Sequence analysis, viruses, Molecular Sequence Data, HIV Infections, Biology, Hemophilia A, medicine.disease_cause, Gene Products, nef, Virus, HIV Long-Term Survivors, Cohort Studies, Virology, medicine, Humans, Amino Acid Sequence, nef Gene Products, Human Immunodeficiency Virus, Cloning, Molecular, Allele, Gene, Alleles, Phylogeny, Genetics, Cloning, Genetic Variation, RNA, virus diseases, Sequence Analysis, DNA, Middle Aged, Simian immunodeficiency virus, Genes, nef, Open reading frame, DNA, Viral, Disease Progression, HIV-1, Leukocytes, Mononuclear, RNA, Viral, Sequence Alignment
Abstract

Deletion of the nei gene results in viral attenuation and confers protection against challenge with wild-type simian immunodeficiency virus in macaques. Regarding HIV-1 infection, a few long-term nonprogressors (LTNP) with nef deletions have been described. In this study, the nef genes of a group of seven LTNP and eight progressors, all belonging to the same cohort of infected hemophiliacs, were analyzed by cloning and sequencing from both virion RNA and peripheral blood mononuclear cell-associated proviral DNA. Defective nef sequences coexisted with full-length nef open reading frames in five of seven LTNP and two of eight progressors. The proportion of disrupted nef sequences within each individual was significantly higher in LTNP (ranging from 10 to 63%) than in progressors (ranging from 9 to 21%) (P = 0.013). Moreover, in-frame small deletions predicting to encode Nef were found in all RNA- and DNA-derived crones from one LTNP and four progressors. A chimeric virus in which the nef gene of NL4.3 was substituted with the nef allele containing the deletion of two alanines at position 49-50 found in two progressors showed a defective replicative capacity compared to NL4.3 virus. In summary, hemophiliacs with either progressing or nonprogressing HIV-1 infection are characterized by the presence of defective nef variants. (C) 1999 Academic Press.

Published
1999
Full Text
View/download PDF

50. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study

Author

Achilles Anagnostopoulos, Serena K. Perna, Veronica Valtolina, Fabio Ciceri, Alessandra Pescarollo, Fulvio Crippa, Evangelia Yannaki, Lucia Turchetto, Zulma Magnani, Athanasios Fassas, Paolo Bruzzi, Maria Teresa Lupo Stanghellini, Catia Traversari, Armando Santoro, Eduardo Olavarria, Luciano Callegaro, Attilio Bondanza, Silvano Rossini, Elisabetta Todisco, Maurilio Ponzoni, Katharina Fleischhauer, Monica Salomoni, Michael Stadler, Elena Spoldi, Claudio Bordignon, Massimo Bernardi, Marco Bregni, Eva M. Weissinger, Corrado Gallo Stampino, Roberto Crocchiolo, Shimon Slavin, Scialini Colombi, Jane F. Apperley, Jacopo Peccatori, Arnold Ganser, Paolo Servida, Chiara Bonini, Luca Vago, Stanghellini, Mtl, Bondanza, Attilio, Traversari, C, Salomoni, M, Turchetto, L, Colombi, S, Bernardi, M, Peccatori, J, Pescarollo, A, Servida, P, Magnani, Z, Perna, Sk, Valtolina, V, Crippa, F, Callegaro, L, Spoldi, E, Crocchiolo, R, Fleischhauer, K, Ponzoni, Maurilio, Vago, L, Rossini, S, Santoro, A, Todisco, E, Apperley, J, Olavarria, E, Slavin, S, Weissinger, Em, Ganser, A, Stadler, M, Yannaki, E, Fassas, A, Anagnostopoulos, A, Bregni, M, Stampino, Cg, Bruzzi, P, Bordignon, Claudio, Ciceri, F, and Bonini, C

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Lymphocyte Transfusion, Transplantation Conditioning, Adolescent, Poison control, Graft vs Host Disease, Thymidine Kinase, Young Adult, Immune system, HLA Antigens, Internal medicine, medicine, Humans, Simplexvirus, Adverse effect, Aged, business.industry, Gene Transfer Techniques, Genes, Transgenic, Suicide, Hematopoietic Stem Cell Transplantation, Suicide gene, Middle Aged, Donor Lymphocytes, Transplantation, Haplotypes, Histocompatibility, Immunology, Female, business
Abstract

Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality. We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality. Methods In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation. The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per mu L or more for two consecutive observations. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00423124. Findings From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17-66) received haploidentical stem-cell transplants for high-risk leukaemia. Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34-127) from transplantation and 23 days (13-42) from infusion. Ten patients developed acute GVHD (grade I-IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene. Overall survival at 3 years was 49% (95% CI 25-73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation. After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days. No acute or chronic adverse events were related to the gene-transfer procedure. Interpretation Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation. Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality. We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality. Methods In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation. The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per mu L or more for two consecutive observations. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00423124. Findings From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17-66) received haploidentical stem-cell transplants for high-risk leukaemia. Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34-127) from transplantation and 23 days (13-42) from infusion. Ten patients developed acute GVHD (grade I-IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene. Overall survival at 3 years was 49% (95% CI 25-73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation. After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days. No acute or chronic adverse events were related to the gene-transfer procedure. Interpretation Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation. Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality. We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality.Methods In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation. The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per mu L or more for two consecutive observations. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00423124.Findings From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17-66) received haploidentical stem-cell transplants for high-risk leukaemia. Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34-127) from transplantation and 23 days (13-42) from infusion. Ten patients developed acute GVHD (grade I-IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene. Overall survival at 3 years was 49% (95% CI 25-73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation. After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days. No acute or chronic adverse events were related to the gene-transfer procedure.Interpretation Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results